InvestorsObserver
×
News Home

Rain Oncology Inc (RAIN) Stock: What Does the Chart Say Wednesday?

Wednesday, January 24, 2024 12:43 PM | InvestorsObserver Analysts

Mentioned in this article

Rain Oncology Inc (RAIN) Stock: What Does the Chart Say Wednesday?

The market has been high on Rain Oncology Inc (RAIN) stock recently. RAIN gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Rain Oncology Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RAIN!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RAIN Stock Today?

Rain Oncology Inc (RAIN) stock is flat 0.4% while the S&P 500 is up 0.73% as of 12:40 PM on Wednesday, Jan 24. RAIN is unchanged $0.00 from the previous closing price of $1.24 on volume of 193,941 shares. Over the past year the S&P 500 is higher by 21.90% while RAIN is lower by -87.31%. RAIN lost -$2.07 per share in the over the last 12 months. To screen for more stocks like Rain Oncology Inc click here.

More About Rain Oncology Inc

Rain Therapeutics Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. Click Here to get the full Stock Report for Rain Oncology Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App